

Rapid progression to toxic epidermal necrolysis

following initially reassuring clinical presentations



Fiona Kimber
Dermatology Advanced Practice Nurse
Canberra Health Services

Stevens—Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening conditions affecting the skin and mucous membranes. They are most commonly triggered by medications and result in extensive epidermal necrosis and skin detachment, causing painful blistering and widespread skin and mucosal shedding.

Case Summary

A woman in her 30's commenced lamotrigine, a recognised trigger for SJS/TEN. She initially presented with a mild rash and stable clinical features. Despite several reassuring clinical presentations, her condition rapidly deteriorated, progressing to TEN and necessitating ICU admission and transfer to a specialist burns unit.

Nursing & Clinical Practice Implications

- Maintain high index of suspicion in patients recently commenced on high risk medications
- Early SJS/TEN may lack mucocutaneous features
- Clear safety-netting and patient education are critical
- Low threshold for re-assessment and escalation

Conclusion

This case demonstrates how SJS/TEN can evolve hours after apparently reassuring clinical assessments. Dermatology, primary care and emergency nurses play a key role in recognising risk, reinforcing safety-netting, and advocating for timely escalation.

Acknowledgement of Country

Canberra Health Services acknowledges the Ngunawal people as traditional custodians of the ACT and recognises any other people or families with connection to the lands of the ACT and region. We acknowledge and respect their continuing culture and contribution to the life of this region.



Accessibility
call 02 5124 0000



Interpreter
call 131 450

canberrahealthservices.act.gov.au/accessibility



MS-9282 | Designed and printed by CHS Multimedia Services
© Australian Capital Territory, Canberra May 2026

Timeline

Early Feb 2026

Lamotrigine commenced - highest risk period for SJS/TEN occurs within the first eight weeks after drug initiation

21 Feb — General Practitioner Review

- Rash noted
- Differential: viral exanthem / drug eruption

23 Feb — Primary Care Clinic (RN & NP Review)

- Spreading blanching maculopapular rash
- Afebrile, systemically well
- No mucosal involvement or blistering
- Safety-netting advice provided
- Patient ceased lamotrigine




Early maculopapular rash

25 Feb 05:38am — First Emergency dept (ED) Presentation

- Rash <10% body surface area, pruritic
- Mucosa spared
- Assessed as unlikely SJS/TEN
- Discharged with safety-netting advice

25 Feb 9:39pm — Same day re-presentation to ED

- Rapid deterioration
- Fever 39—40°C, tachycardia
- Severe skin pain
- Blistering skin lesions
- Oral and ocular mucosal involvement



Confluent erythema with early epidermal detachment

26 - 27 Feb — Escalation of Care

- Diagnosed SJS progressing to TEN
- Etanercept administered following dermatology input
- Transfer to tertiary hospital → burns unit



Extensive epidermal detachment

Acknowledgements

The author would like to acknowledge all staff involved in the care of this patient, including the CHS Dermatology Department; primary health clinicians Vishnu Ram and Anne McLaughlan; and the Emergency Department, Intensive Care Unit, and support staff.